## BMY: Bristol-Myers Squibb Company - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.0% below STRENGTH zone (3.0-6.0%); PEG 2.26 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.4% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($51.88)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Bristol Myers Squibb (BMY) Stock: Weekend News, Analyst Targets, Dividend Update, and What to Watch Before Monday’s Open**
- Source: ts2.tech | 20251228T202814 | Neutral | Relevance: 100%
- Bristol Myers Squibb (BMY) stock ended the week at $54.64, with investors weighing the company's defensive profile and dividend appeal against upcoming patent expirations. Recent news includes institutional activity, mixed analyst targets averaging around $53.93-$59.50, and key pipeline developments for Opdivo and neuroscience programs. The company also announced a 1.6% dividend increase and investors are watching policy implications, especially regarding the Eliquis agreement with the U.S. government, as they head into Monday's trading session and Q4 2025 earnings in February 2026.

**2. Bristol-Myers Squibb (BMY) Stock: What Investors Should Watch Before Monday’s Open as Dividend Date, Earnings, and 2026 Catalysts Come Into Focus**
- Source: ts2.tech | 20251227T225136 | Somewhat-Bullish | Relevance: 100%
- Bristol-Myers Squibb (NYSE: BMY) is heading into the end of 2025 with investor attention on its dividend timeline, upcoming earnings, and key 2026 regulatory and pipeline milestones. The stock finished Friday at about $54.65, with analysts holding mixed views and a consensus "Hold" rating. Investors should particularly watch the dividend record date of January 2, 2026, the Q4 2025 earnings report expected on February 5, 2026, and a PDUFA goal date of April 8, 2026, for Opdivo.

**3. Bristol-Myers Squibb (BMY) Stock: Weekend Market Close, Fresh Institutional Filings, and What to Watch Before Monday’s Open**
- Source: ts2.tech | 20251227T204532 | Neutral | Relevance: 100%
- Bristol-Myers Squibb (BMY) stock is heading into the weekend with U.S. equity markets closed, after essentially flat trading typical of late-December. Investors are reviewing fresh institutional ownership updates, with several firms adjusting their positions, and monitoring catalysts like the upcoming dividend payment and the evolving U.S. drug pricing environment. The company's Q4 2025 results are scheduled for February 5, 2026, which will be the next major scheduled catalyst for the stock currently trading within a range, balanced between income appeal and longer-term growth questions.

**4. Bristol Myers Squibb stock slips today as year-end trading thins and dividend date nears**
- Source: ts2.tech | 20251229T141500 | Somewhat-Bearish | Relevance: 100%
- Bristol Myers Squibb (BMS) stock slipped today by about 0.7%, underperforming the broad market in thin year-end trading. Investors are anticipating the company's January 2nd shareholder record date for its next dividend and its February 5th earnings report. The stock's movement is also influenced by year-end rebalancing and tax-loss harvesting, with traders watching for sustained pressure on defensive sectors and upcoming Federal Reserve communications.

**5. Bristol Myers Squibb Company $BMY Stock Holdings Reduced by Valley National Advisers Inc.**
- Source: MarketBeat | 20251229T111806 | Somewhat-Bullish | Relevance: 100%
- Valley National Advisers Inc. significantly reduced its stake in Bristol Myers Squibb (NYSE:BMY) by 82.8% in Q3, selling 28,312 shares and retaining 5,891 shares valued at $265,000. Despite this reduction from one firm, institutional investors collectively hold 76.41% of the stock. Bristol Myers Squibb reported strong Q3 earnings, beating EPS estimates, and has raised its quarterly dividend to $0.63, reflecting a 4.6% annualized yield.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | B of A Securiti | $61 | $52 | +17% |
| 2025-12-12 | Morgan Stanley | $37 | $36 | +3% |
| 2025-12-12 | Guggenheim | $62 | $0 | 0% |
| 2025-12-10 | Wells Fargo | $55 | $53 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | B of A Securiti | up | Buy |
| 2025-12-12 | Morgan Stanley | main | Underweight |
| 2025-12-12 | Guggenheim | up | Buy |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($0.00M) |
| Sells | 3 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 41.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.5%)
- Blackrock Inc.: 8.6% (+1.9%)
- JPMORGAN CHASE & CO: 8.5% (+65.8%)
- State Street Corpora: 4.7% (+2.0%)
- Charles Schwab Inves: 3.6% (+3.2%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-3.4% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 5 raises (avg +11%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.26 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 34%). Balance sheet: $6.0B free cash flow. Revenue declining -8% YoY, concerning. Analyst sentiment positive (5 raises, avg +11%). Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $110.2B |
| Beta | 0.30 |
| 52W Range | $42.52 - $63.33 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.26 |
| Forward P/E | 9.0 |
| Current P/E | 8.3 |
| YoY Growth | -8.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 2.4% to -1.0% (-3.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.0pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.96% (CS: 35) | Neutral |
| RSI_14 | 64.9 | Neutral |
| MACD Histogram | -0.02 | Bearish |
| vs SMA20 | 1.029x | Above |
| vs SMA50 | 1.111x | Above |
| vs SMA200 | 1.113x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $54.12
- **Stop Loss:** $51.88 (4.1% risk)
- **Target:** $56.36 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 616
- **Position Value:** $33,337.92
- **Portfolio %:** 33.34%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite and defensive rotation. VIX at 14.2 (2nd percentile) signals low volatility, while positive yield curve (+58bps) and stable economic indicators support continued expansion. Market breadth at 58.7% shows decent participation, but rotation into defensive names and Fed liquidity concerns warrant measured positioning.*

### Earnings

**Next:** 2026-02-05 (Est: $1.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.52 | $1.63 | +7.6% |
| 2025Q2 | $1.10 | $1.46 | +32.6% |
| 2025Q1 | $1.50 | $1.80 | +19.9% |
| 2024Q4 | $1.47 | $1.67 | +13.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*